Recombinant Human Olfactory receptor 10J5 (OR10J5)

What is OR10J5 and where is it expressed beyond the olfactory epithelium?

OR10J5 is a G-protein-coupled receptor belonging to the olfactory receptor family. While traditionally associated with olfactory sensory neurons, OR10J5 demonstrates significant ectopic expression in multiple tissues. It has been conclusively identified in the human aorta, coronary artery, umbilical vein endothelial cells (HUVEC) , and hepatocytes . Expression mapping has also suggested presence in other non-chemosensory tissues according to transcriptomic analyses . This ectopic expression pattern suggests broader physiological roles beyond olfactory perception, making it an intriguing target for diverse research applications in cardiovascular biology, metabolism, and other fields.

What are the confirmed ligands for OR10J5?

Current research has identified two principal ligands for OR10J5. The first is lyral, a synthetic floral odorant that has been shown to activate OR10J5 and induce calcium signaling and AKT phosphorylation in HUVEC cells . The second confirmed ligand is α-cedrene, a natural sesquiterpene constituent of cedarwood oil derived from Cupressus and Juniperus species . Both compounds bind to OR10J5 with sufficient specificity to trigger downstream signaling cascades. When designing experiments involving OR10J5 activation, researchers should consider using these validated ligands at concentrations established in previous studies to ensure reliable receptor activation and downstream pathway engagement.

What is the basic structure of OR10J5 and how does it bind to ligands?

OR10J5, like other olfactory receptors, has a 7-transmembrane domain structure characteristic of G-protein-coupled receptors . Computational binding studies have revealed that the interaction between lyral and OR10J5 specifically involves five amino acid residues: Phe104, Val105, Cyx178, Ile180, and Tyr258 . These residues are strategically located within the receptor structure: two on transmembrane domain 3 (TM3), two on extracellular loop 2 (EL2), and one on transmembrane domain 6 (TM6) . Understanding this binding profile is essential for researchers designing experiments involving site-directed mutagenesis, protein engineering, or pharmacological manipulation of OR10J5 function.

What methods are most effective for studying OR10J5 expression in tissue samples?

Multiple complementary techniques have proven effective for detecting OR10J5 expression. For initial screening, reverse transcription polymerase chain reaction (RT-PCR) provides sensitive detection of OR10J5 mRNA in various tissues . For protein-level confirmation, Western blotting with validated antibodies against OR10J5 is recommended . Immunohistochemistry or immunofluorescence assays provide valuable spatial information about receptor localization within tissues. For comprehensive expression analysis, RNA sequencing approaches have revealed detailed expression patterns across multiple tissues . Researchers should employ at least two independent methods to confirm expression, ideally combining nucleic acid-based detection with protein verification to avoid artifacts associated with single-method approaches.

How can researchers effectively conduct knockdown studies to investigate OR10J5 function?

RNA interference (RNAi) has been successfully used to interrogate OR10J5 function in multiple cell types. In HUVEC cells, OR10J5 knockdown inhibited lyral-induced calcium signaling and AKT phosphorylation, confirming the receptor's role in these processes . In hepatocytes, siRNA-mediated knockdown of OR10J5 increased intracellular lipid accumulation, altered expression of lipogenic genes, and downregulated fatty acid oxidation genes . When designing knockdown experiments, researchers should include appropriate controls (scrambled siRNA sequences), validate knockdown efficiency by qPCR and Western blot, and examine multiple downstream effects to comprehensively characterize OR10J5 function. Parallel experiments with known OR10J5 ligands can further validate the specificity of observed knockdown effects.

What functional assays are most informative for studying OR10J5 activity?

Several functional assays have proven valuable for investigating OR10J5 activity across different experimental systems. Calcium flux assays measuring intracellular Ca²⁺ levels following ligand stimulation effectively demonstrate OR10J5 activation . Phosphorylation assays for AKT can detect downstream signaling events after receptor activation . For HUVEC studies, migration assays and Matrigel plug assays have successfully measured the angiogenic effects of OR10J5 activation . In hepatocytes, lipid accumulation assays combined with gene expression analysis of metabolic markers effectively quantify OR10J5's impact on lipid metabolism . Researchers should select assays that align with the specific physiological process under investigation while maintaining appropriate controls for ligand specificity and receptor dependency.

How does OR10J5 activation influence calcium signaling and what methodologies best capture this relationship?

OR10J5 activation by ligands such as lyral induces calcium (Ca²⁺) flux in responsive cells including HUVEC . This calcium signaling appears to be a critical early event in the signal transduction cascade. For experimental investigation, researchers should consider employing calcium-sensitive fluorescent dyes (e.g., Fura-2 AM) combined with real-time imaging to capture dynamic calcium responses. Calcium chelators can be used as controls to confirm the calcium dependency of downstream effects. Patch-clamp electrophysiology provides more detailed insights into the ionic mechanisms involved. Importantly, knockdown studies have confirmed that lyral-induced calcium signaling is mediated specifically by OR10J5, as RNAi targeting the receptor inhibits this response , suggesting a direct mechanistic link between receptor activation and calcium mobilization.

What is the relationship between OR10J5 activation and AKT signaling pathways?

OR10J5 activation leads to phosphorylation of AKT, a crucial signaling molecule involved in cellular growth, survival, and metabolism . In HUVEC cells, lyral stimulation of OR10J5 activates a Ca²⁺-dependent AKT signal transduction pathway that regulates angiogenesis and cellular migration . This relationship has been confirmed through knockdown studies showing that OR10J5 silencing inhibits lyral-induced AKT phosphorylation . For researchers investigating this pathway, Western blot analysis with phospho-specific antibodies against AKT, combined with upstream inhibitors of calcium signaling and downstream AKT inhibitors, can help delineate the specific components of this signaling cascade. Time-course experiments are particularly valuable for establishing the temporal dynamics of OR10J5-mediated AKT activation.

How does OR10J5 interact with the cAMP-PKA pathway in hepatocytes?

In hepatocytes, OR10J5 activation by α-cedrene engages the cAMP-PKA (cyclic adenosine monophosphate-protein kinase A) pathway to regulate lipid metabolism . This signaling mechanism differs from the calcium-AKT pathway observed in endothelial cells, highlighting the context-dependent nature of OR10J5 signaling. When investigating this pathway, researchers should measure intracellular cAMP levels using ELISA or FRET-based biosensors following ligand stimulation. PKA activity assays can confirm downstream activation. Pharmacological inhibitors of adenylyl cyclase (which produces cAMP) or PKA can help validate pathway specificity. Gene expression analysis of PKA-responsive genes provides further evidence of pathway engagement. This comprehensive approach can establish the mechanistic link between OR10J5 activation and metabolic reprogramming in hepatocytes.

What is the role of OR10J5 in angiogenesis and how can this be studied experimentally?

OR10J5 has been identified as a key regulator of angiogenesis, with its activation by lyral enhancing migration of human umbilical vein endothelial cells (HUVEC) . In vivo evidence from Matrigel plug assays has confirmed that lyral stimulation enhances angiogenesis through OR10J5-mediated mechanisms . To investigate this function, researchers should employ a combination of in vitro and in vivo techniques. Cell migration assays (wound healing, Boyden chamber) can quantify the migratory response of endothelial cells following OR10J5 activation. Tube formation assays assess the capacity of endothelial cells to form vessel-like structures on extracellular matrix substrates. For in vivo validation, Matrigel plug assays provide a well-established method to quantify functional angiogenesis. Receptor specificity should be confirmed through knockdown/knockout approaches or competitive antagonists when available.

How does OR10J5 regulate lipid metabolism in hepatocytes?

OR10J5 plays a crucial role in regulating lipid accumulation in human hepatocytes . RNA interference-mediated knockdown of OR10J5 increases intracellular lipid accumulation, upregulates lipogenic genes, and downregulates genes related to fatty acid oxidation . Conversely, stimulation with the OR10J5 agonist α-cedrene significantly reduces lipid content in hepatocytes and reprograms metabolic gene expression profiles . These effects appear to be mediated through the OR10J5-cAMP-PKA pathway . For experimental investigation, researchers should quantify intracellular lipid accumulation using Oil Red O staining or BODIPY labeling, measure expression of key metabolic genes (SREBP-1c, FAS, CPT1) by qPCR, and assess fatty acid oxidation rates using radiolabeled substrates or oxygen consumption measurements. Combined with receptor manipulation approaches, these methods can provide comprehensive insights into OR10J5's metabolic functions.

What evidence supports OR10J5's role in dermatological conditions like contact dermatitis?

Computational binding studies have established a structural relationship between lyral, a known allergen that produces contact dermatitis, and its binding to OR10J5 . The binding interaction involves specific amino acid residues (Phe104, Val105, Cyx178, Ile180, and Tyr258) within the OR10J5 structure . While this suggests a potential role for OR10J5 in mediating dermatological responses to certain allergens, further functional validation is needed. Researchers investigating this connection should consider patch testing with lyral in conjunction with OR10J5 expression analysis in skin samples, immunohistochemical localization of OR10J5 in different skin layers, and ex vivo skin models to evaluate inflammatory marker expression following lyral exposure. Animal models with tissue-specific OR10J5 manipulation could provide additional insights into the receptor's role in allergic dermatitis.

What are the critical considerations for heterologous expression of OR10J5 in experimental systems?

Heterologous expression of OR10J5 presents significant challenges due to the poor trafficking of olfactory receptors to the plasma membrane in non-native cell types. Successful surface expression has been achieved using specialized expression systems such as Hana3A cells . When establishing an OR10J5 expression system, researchers should incorporate N-terminal epitope tags (such as FLAG or Rho tags) to facilitate detection while avoiding interference with ligand binding. Surface expression should be verified through multiple complementary techniques including Western blotting of surface proteins, confocal microscopy, and flow cytometry . Based on published methodologies, approximately 50% surface expression efficiency can be achieved in optimized systems . Controlling for expression levels and ensuring proper membrane localization are critical for obtaining physiologically relevant results in functional studies.

How can researchers resolve contradictions between OR10J5 signaling pathways in different tissues?

OR10J5 activation triggers distinct signaling pathways in different cellular contexts: a Ca²⁺-dependent AKT pathway in endothelial cells versus a cAMP-PKA pathway in hepatocytes . These differences likely reflect tissue-specific expression of G-protein subunits, accessory proteins, or downstream effectors. To resolve these contradictions, researchers should conduct comprehensive G-protein coupling assays using techniques such as BRET (bioluminescence resonance energy transfer) or FRET to determine which G-protein subtypes interact with OR10J5 in each cell type. Comparative transcriptomics or proteomics of different OR10J5-expressing tissues can identify cell-specific cofactors that might direct signaling specificity. Additionally, simultaneous measurement of multiple second messengers (Ca²⁺, cAMP, IP₃) following OR10J5 activation in different cell types can establish the primary signaling modality in each context.

What approaches should be used to investigate potential physiological ligands for OR10J5 beyond currently known agonists?

While lyral and α-cedrene are confirmed OR10J5 agonists , the natural physiological ligands in different tissues remain largely speculative. To identify novel ligands, researchers should implement a multi-faceted discovery approach. Computational screening based on the known binding structure with lyral can identify candidates with similar chemical features. High-throughput screening using cell-based reporter assays (measuring calcium, cAMP, or other second messengers) can efficiently test large compound libraries. Metabolomic profiling of tissues where OR10J5 is expressed may reveal endogenous molecules capable of receptor activation. Validation of candidate ligands should include dose-response analyses, competitive binding assays against known ligands, and confirmation of specificity through receptor knockdown experiments. This comprehensive approach may uncover tissue-specific endogenous ligands that explain the diverse physiological roles of OR10J5.

What potential exists for targeting OR10J5 in metabolic disorders such as hepatic steatosis?

OR10J5 activation by α-cedrene significantly reduces lipid content in human hepatocytes and reprograms metabolic gene expression through the cAMP-PKA pathway . This suggests therapeutic potential for OR10J5 agonists in treating hepatic steatosis. Researchers exploring this application should conduct preclinical studies using both cell culture models of steatosis (e.g., free fatty acid-loaded hepatocytes) and animal models of non-alcoholic fatty liver disease. Key endpoints should include quantitative assessment of hepatic triglyceride content, histological evaluation of lipid droplets, comprehensive metabolic profiling, and analysis of inflammatory markers. Long-term studies are necessary to evaluate the sustainability of metabolic improvements and potential compensatory mechanisms. Additionally, tissue-specific delivery strategies should be developed to target hepatic OR10J5 while minimizing off-target effects in other OR10J5-expressing tissues.

How might the angiogenic properties of OR10J5 be leveraged in regenerative medicine?

The established role of OR10J5 in promoting endothelial cell migration and angiogenesis presents opportunities for applications in wound healing, tissue engineering, and ischemic disease treatment. Researchers investigating these applications should develop controlled-release systems for OR10J5 agonists like lyral, potentially incorporating them into biomaterials or tissue scaffolds. Efficacy should be evaluated in models of impaired wound healing or tissue ischemia, with quantitative assessment of vascular density, tissue perfusion, and functional recovery. Potential synergistic effects with established pro-angiogenic factors (VEGF, FGF) warrant investigation through combination studies. Safety assessments must carefully evaluate the risk of pathological angiogenesis or tumor vascularization. As translational development progresses, pharmacokinetic/pharmacodynamic modeling will be essential for optimizing dosing regimens and delivery strategies.

What are the technical challenges and potential solutions for developing specific OR10J5 modulators for research applications?

Developing highly specific modulators (agonists or antagonists) for OR10J5 presents significant challenges due to the structural similarity among olfactory receptors. Structure-based drug design approaches, informed by the known binding interactions of lyral and α-cedrene , offer promising pathways for developing selective compounds. Researchers should establish reliable high-throughput screening systems using OR10J5-expressing cell lines with appropriate reporter assays. Counter-screening against closely related olfactory receptors is essential to confirm specificity. Medicinal chemistry optimization should focus on enhancing selectivity while maintaining favorable pharmacokinetic properties. For research applications, the development of tool compounds with orthogonal chemical structures but similar functional effects can help validate the specificity of observed biological responses. Additionally, photoaffinity labeling probes or fluorescent ligands could provide valuable tools for visualizing receptor localization and trafficking dynamics in living cells.

Table 1: Key Experimental Systems for Studying OR10J5 Functions